Navigation Links
STAAR Surgical Generates Cash From Operations During Second Quarter
Date:8/3/2009

MONROVIA, Calif., Aug. 3 /PRNewswire-FirstCall/ -- STAAR Surgical Company (Nasdaq: STAA), a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today reported that it generated $286,000 in cash from operating activities during the second quarter. The cash generation marked the first time since the first quarter of 2003 that the company generated cash from operating activities. This milestone was made possible due to improvement in sales mix and the significant progress in the management of operating expenses and working capital. That progress also contributed to the positive EBTIDA reported during the quarter and year to date, which STAAR has not achieved since the first quarter of 2003.

Second Quarter Financial Highlights

  • Cash provided by operating activities was $286,000, compared to cash used in operating activities of $2.8 million during the second quarter of 2008. This reflects continuous improvement for the past six quarters as shown below:

         Cash Provided by (Used in) Operating Activities (000's)
        Q1 2008     Q2 2008    Q3 2008   Q4 2008   Q1 2009    Q2 2009
         $(3,370)   $(2,760)   $(1,107)   $(991)    $(448)     $286

  • Global sales for the second quarter were $19.1 million, or $19.8 million on a constant currency basis, as compared to $20.7 million during the second quarter of 2008. Global sales for the second quarter of 2009 were impacted by the Company's decision in late 2008 to de-emphasize sales of low margin products. Sales of these lower margin products declined by 23.5% or $1.5 million during the second quarter.
  • Gross profit margin was 55.8%, unchanged from the second quarter of 2008.
  • Operating expenses declined by 16% to $11.3 million from $13.5 million reported for the second quarter of 2008. Operating expense as a percentage of total revenue dropped to 59% compared to 65% reported for the prior year quarter.
  • Operating loss improved by $1.3 million, which is a 67% decrease from the $2.0 million loss reported in the second quarter of 2008.
  • EBITDA for the second quarter was $360,000 and year to date was $136,000 reflecting the first positive EBITDA generated for any quarterly period by the Company since the first quarter of 2003.

Recent Visian ICL Highlights

  • Global Visian ICL units grew 29% during the second quarter of 2009 versus the second quarter of 2008. Sequentially, global Visian ICL units increased by 21% from the first quarter of 2009 and year to date global Visian ICL units are up 28%.
  • International Visian ICL sales grew to $4.4 million, which is a 12% increase compared to the $4.0 million sales reported in the prior year second quarter. International Visian ICL units grew 42% from the year ago period and are up 35% year to date reflecting the increased underlying demand for the Visian products despite the global economic downturn. Revenue growth was negatively impacted by the weakness of international currencies, primarily the Euro, versus the dollar.
  • U.S. Visian ICL units were down 18% during the second quarter versus an estimated 45% decline in LASIK procedures in the U.S. during the second quarter which reflects a continued growth in market share. Year to date, U.S. Visian ICL units were essentially flat compared with the first six months of 2008 compared to an estimated 40% decline in LASIK procedures.
  • On July 17, the U.S. Food and Drug Administration (FDA) Division of Bioresearch Monitoring informed the Company that the restrictions of the "integrity hold" put in place by the FDA on August 3, 2007 have been removed. The removal of the integrity hold has now allowed the FDA to resume scientific review of the STAAR application for the Toric Implantable Collamer Lens (TICL(TM)) for Myopic/Astigmatic patients.
  • The Expert Panel Meeting of Japan's Ministry of Health Labor and Welfare regarding the Visian ICL and Visian Toric ICL was held the last week of July. The panel's recommendation is expected within the next two weeks.

Recent Intraocular Lens (IOL) Highlights

  • Global IOL sales were $8.5 million versus $8.7 million in the prior year second quarter. Units were up 2.4% during the second quarter and are up one-half of one percent during the first half of the year. Global IOL units increased sequentially 7.5% in the second quarter
  • International IOL sales were $6.2 million versus $6.4 million in the prior year second quarter and increased 3% sequentially. During the quarter international IOL unit sales increased by 4% compared with 2008 and 12% sequentially. Units in Japan increased by 5% and units in Germany by 4% during the quarter.
  • U.S. IOL sales were flat compared to the second quarter of 2008, at $2.3 million. Silicone IOL sales increased 19% in the second quarter year over year and are up 9% for the first six months of the year due to conversion to NTIOL product lines. Toric IOL sales increased by 2% while Collamer(R) IOL sales were down 13%. U.S. IOL sales increased 8% sequentially.
  • Recent regulatory approvals provide additional revenue opportunities for the second half of the year. The nanoFLEX Collamer Aspheric IOL with the nanoPOINT Injector System which allows for implantation through a 2.2 mm incision, and the recently approved Epiphany Injector System for the Afinity(TM) Three-Piece Collamer will be available in the U.S. for sale during the third quarter. The KS-X Preloaded Hydrophobic Acrylic Injector System, which received CE Marking, will be available for the international markets during the third quarter.
  • Members of the Collamer Accommodating Study Team (CAST) reported surpassing 200 patient eye implants with the nanoFLEXCollamer Aspheric Single Piece IOL. Though early, the initial data is very encouraging and the Company expects that members of the CAST will present results during the American Academy of Ophthalmology meeting in October and the Company will determine the next steps during the fourth quarter.

"The STAAR team has accomplished a major goal with the generation of cash from operating activities as well as EBITDA during the second quarter. These significant milestones, six years in the making, were achieved by the successful execution by the management team of our sales strategy, which is focused on higher margin products, and vigilant control of costs. What's most important now is that we stay on track to generate cash from operating activities in the third and fourth quarters of this year and move to achieve positive net income," commented Barry G. Caldwell, President and CEO.

"While our sales growth year to date has been impacted by our decision to de-emphasize sales of lower margin products, we are optimistic that we will achieve growth in both our Visian ICL and IOL lines for the second half of the year," Mr. Caldwell continued. "The FDA's decision to remove the integrity hold that halted scientific review of our Visian Toric ICL means that review of our PMA supplement has resumed. In addition, we are making progress in the regulatory process towards the approval of the Visian ICL and Visian Toric ICL in Japan. On the IOL front, our newly released nanoFLEX Collamer Aspheric IOL combined with the nanoPOINT Injector System and our newly approved Epiphany injector system for the Three Piece Collamer Aspheric IOL is expected to create growth in the U.S. market during the second half of the year. These developments lead us to a favorable outlook for the second half and 2010 while our continued efforts to reduce costs remain a daily focus at our company. We believe we are on plan to generate cash from operations for the full year, improve overall gross margin, decrease operating expense and move to profitability," added Mr. Caldwell.

Financial Performance for the Second Quarter Ended July 3, 2009

Gross profit for the second quarter was $10.7 million compared with $11.5 million, which was 55.8% of net sales in both periods. Gross profit margin was flat year over year as a result of lower ASPs on IOLs and ICLs and higher unit costs due to decreased manufacturing volume as part of an effort to reduce inventories, offset by the favorable effect of increased volume and mix. Gross profit for the first six months of 2009 was $21.0 million, or 56% of net sales, compared with $19.3 million, or 50% of net sales in the prior year period. Gross profit for the first six months of 2008 was negatively impacted by a $1.5M purchase accounting charge associated with the acquisition of STAAR Japan.

Continued improvement in the management of operating expenses during the second quarter resulted in a $2.2 million dollar reduction or 16% from the year ago period. Sales and marketing expenses were reduced by $1.6 million during the quarter. Research and Development declined by $900,000 as a result of the Center of Excellence project and reduced regulatory consulting fees, although the investment level is still 10.4% of all STAAR manufactured product sales.

Net loss for the second quarter ended July 3, 2009 was $1.1 million or $0.04 per share, compared with $2.5 million, or $0.09 per share for the second quarter of 2008. Non-cash charges for the quarter were $1.4 million or $0.04 per share. For the six months ended July 3, 2009, the net loss was $2.8 million, or $0.09 per share, compared with a net loss of $11.5 million, or $0.39 per share for the first half of 2008. During the first six months of 2009, non-cash charges were $2.9 million or $0.09 per share. Purchase accounting charges associated with the acquisition of STAAR Japan impacting the first six months of 2008 were $5.4 million or $0.18 per share.

On July 3, 2009, the Company reported cash, cash equivalents and restricted cash of $13.1 million compared with $5.2 million at the end of 2008 and $3.7 million at the end of the first quarter of 2009. During the quarter, the Company raised $8.6 million to fund a deposit as a guarantee for the judgment in the Parallax case pending appeal.

Conference Call

The Company will host a conference call and webcast on Monday, August 3, 2009 at 8:30 a.m. Eastern Time to discuss the Company's second quarter and current corporate developments. The dial-in number for the conference call is 877-941-1848 for domestic participants and 480-629-9722 for international participants.

A taped replay of the conference call will also be available beginning approximately one hour after the call's conclusion and will be available for seven days. This replay can be accessed by dialing 800-406-7325 for domestic callers and 303-590-3030 for international callers, both using passcode 4117561#. To access the live webcast of the call, go to STAAR Surgical's website at www.staar.com. An archived webcast will also be available at www.staar.com.

About STAAR Surgical

STAAR Surgical is a leader in the development, manufacture and marketing of minimally invasive ophthalmic products employing proprietary technologies. STAAR's products are used by ophthalmic surgeons and include the Visian ICL, a tiny, flexible lens implanted to correct refractive errors, as well as innovative products designed to improve patient outcomes for cataracts and glaucoma. Manufactured in Switzerland by STAAR, the ICL is approved by the FDA for use in treating myopia, has received CE Marking and is sold in more than 50 countries. Collamer(R) is the brand name for STAAR's proprietary collagen copolymer lens material. More information is available at www.staar.com.

Safe Harbor

All statements in this press release that are not statements of historical fact are forward-looking statements, including statements about any of the following: projections of earnings, revenue, sales, cash or any other financial items; the plans, strategies, and objectives of management for future operations or prospects for achieving such plans; future sale; prospects for approval of the Visian Toric ICL supplemental premarket approval application, or any other future approval by the FDA or other regulatory agencies; our future performance; statements of belief; and any statements of assumptions underlying any of the foregoing.

These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties include our limited capital resources and limited access to financing, the fact that our public accounting firm has expressed doubt about our ability to continue as a going concern in their opinion on our financial statements, the broad discretion of the FDA in approving any medical device and the inherent uncertainty that new devices will be approved, the likelihood of administrative delays, the need in certain future FDA submissions to satisfy additional and potentially costly requirements such as third party audits, the cost of defending pending litigation and satisfying judgment in the event of an adverse ruling, for which we have taken no reserve, the negative effect of the global recession on sales of products, especially products such as the ICL used in non-reimbursed elective procedures, the challenge of managing our foreign subsidiaries, the risk that sales of our newly introduced products may not restore profitability to our U.S. IOL product line, our ability to overcome negative publicity resulting from warning letters and other correspondence from the FDA Office of Compliance and to demonstrate to the agency that its past concerns have been resolved, the willingness of surgeons and patients to adopt a new product and procedure, and the potential effect of recent negative publicity about LASIK on the demand for refractive surgery in general in the U.S. STAAR assumes no obligation to update its forward-looking statements to reflect future events or actual outcomes and does not intend to do so.

Use of Non-GAAP Information

This news release presents selected items from the Company's Condensed Consolidated Statements of Operations as reported in accordance with U.S. generally accepted accounting principles ("GAAP"), and also on a non-GAAP basis after excluding certain non-recurring expenses, and excluding changes in currency. Additionally, this news release contains a discussion of EBITDA which is also a non-GAAP measure of performance. None of these measures are a substitute for measures determined in accordance with GAAP, and may not be comparable to the same measures as reported by other companies.

"EBITDA" is defined as earnings before net interest, income taxes, depreciation and amortization. EBITDA is a widely accepted measure of operating profitability because it excludes non-operating expenses and noncash charges that can mask trends in core performance. STAAR's management uses EBITDA to track the company's progress toward profitability and measure its core performance. The Company believes this measure of performance might also be useful to investors for the same reasons. The table below presents EBITDA and reconciles it to net earnings (loss).

When reviewing financial information to assess the effectiveness of initiatives to enhance long-term performance by reducing expenses, management may eliminate the effect of significant non-recurring expenses in order to discern underlying trends. In the 2008 fiscal year, the Company's results were significantly affected by the following non-recurring expenses classified in the GAAP reconciliation table as "purchase A/C [accounting] charges": a $1.5 million purchase accounting charge related to inventory purchased in the acquisition of STAAR Japan, Inc. and a $3.8 million charge for the settlement of a pre-existing distribution arrangement in connection with the STAAR Japan, Inc. acquisition. Because the effect of purchase accounting charges can overwhelm the effect of meaningful trends in the Company's business performance, management evaluates its performance excluding these non-recurring items. The Company believes that this non-GAAP measure is also helpful to investors in discerning underlying trends. The table below shows the effects of the excluded non-recurring items.

The Company conducts a significant part of its activities outside the U.S. It receives sales revenue and pays expenses principally in U.S. dollars, Swiss francs, Japanese yen and Euros. The exchange rates between dollars and non-U.S. currencies can fluctuate greatly and can have a significant effect on our results when reported in U.S. dollars. When preparing its financial statements in conformance with GAAP, the Company translates foreign currency sales and expenses to dollars at the weighted average of exchange rates in effect during the period. As a result, the Company's reported performance may be significantly affected by currency fluctuations. In order to compare the Company's performance from period to period without the effect of currency, the Company will apply the same average exchange rate applicable in the prior period, or the "constant currency" rate to sales or expenses in the current period as well. Because changes in currency are outside of the control of the Company and its managers, management finds this non-GAAP measure useful in determining the long term progress of its initiatives and determining whether its managers are achieving their performance goals. The Company believes that the non-GAAP constant-currency sales results measures provided in this press release are similarly useful to investors to give insight on long term trends in the Company's performance without the external effect of changes in relative currency values. The table below shows sales results calculated in accordance with GAAP, the effect of currency, and the resulting non-GAAP measure expressed in constant currency.

    CONTACT:   Investors                       Media
               EVC Group                       EVC Group
               Douglas Sherk, 415-896-6820     Christopher Gale 646-201-5431
               Michael Pollock, 415-896-5862

    (Tables to Follow)



    STAAR Surgical Company
    Condensed Consolidated Statements of Operations
    (In 000's except for per share data)
    Unaudited

                                                  Three Months Ended
                                                  ------------------
                                           % of    July 3,    % of   June 27,
                                           sales    2009     sales     2008
                                           -----    ----     -----     ----

    Net sales                              100%   $19,117     100%   $20,665

    Cost of sales                           44%     8,453      44%     9,131
                                                    -----              -----

    Gross profit                            56%    10,664      56%    11,534
                                                   ------             ------

    Selling, general and administrative
     expenses:
      General and administrative            20%     3,855      17%     3,520
      Marketing and selling                 32%     6,032      37%     7,646
      Research and development               8%     1,441      11%     2,357
      Loss on settlement of pre-existing
       distribution arrangement              0%         -       0%         0
                                                      ---                ---
         Total selling, general and
          administrative expenses:          59%    11,328      65%    13,523
                                                   ------             ------
    Operating loss                          -3%      (664)    -10%    (1,989)
                                                     ----             ------
    Other income (expense):
      Interest income                        0%         5       0%        63
      Interest expense                      -2%      (399)     -1%      (222)
      Gain on foreign currency               1%       122       0%        16
      Other income, net                      1%       128       0%       (17)
                                                      ---                ----
        Other (expense) income, net         -1%      (144)     -1%      (160)
                                                      ---                ----
    Loss before provision for income
     taxes                                  -4%      (808)    -10%    (2,149)

    Provision for income taxes               1%       280       2%       396
                                                      ---                ---
    Net loss                                -6%   $(1,088)    -12%   $(2,545)
                                                  =======            =======
    Loss per share:
    Basic and diluted                              $(0.04)            $(0.09)
                                                   ======             ======
    Weighted average shares outstanding:
    Basic and diluted                              30,911             29,488
                                                   ======             ======



                                                  Six Months Ended
                                                  ----------------
                                           % of    July 3,    % of   June 27,
                                           sales    2009     sales     2008
                                           -----    ----     -----     ----
    Net sales                              100%   $37,400     100%   $38,625

    Cost of sales                           44%    16,397      50%    19,336
                                                   ------             ------
    Gross profit                            56%    21,003      50%    19,289
                                                   ------             ------
    Selling, general and administrative
     expenses:
      General and administrative            22%     8,137      21%     7,961
      Marketing and selling                 32%    11,811      37%    14,113
      Research and development               8%     2,853      11%     4,075
      Loss on settlement of pre-existing
       distribution arrangement              0%         -      10%     3,850
                                                      ---              -----
         Total selling, general and
          administrative expenses:          61%    22,801      78%    29,999
                                                   ------             ------
    Operating loss                          -5%    (1,798)    -28%   (10,710)
                                                    -----             ------
    Other income (expense):
      Interest income                        0%         8       0%        91
      Interest expense                      -2%      (632)     -1%      (423)
      Gain on foreign currency               1%       197       0%       144
      Other income, net                      1%       191       0%        67
                                                      ---                 --
        Other (expense) income, net         -1%      (236)      0%      (121)
                                                      ---                ---
    Loss before provision for income taxes  -5%    (2,034)    -28%   (10,831)

    Provision for income taxes               2%       716       2%       654
                                                      ---                ---
    Net loss                                -7%   $(2,750)    -30%  $(11,485)
                                                  =======           ========
    Loss per share:
    Basic and diluted                              $(0.09)            $(0.39)
                                                   ======             ======
    Weighted average shares outstanding:
    Basic and diluted                              30,276             29,488
                                                   ======             ======



    STAAR Surgical Company
    Global Sales
    (in 000's)
    Unaudited


                        Three Months Ended          Six Months Ended
                        ------------------          ----------------

                      July 3, June 27,   %      July 3, June 27,    %
    Geographic Sales    2009    2008  Change      2009    2008   Change
                        ----    ----  ------      ----    ----   ------
    United States     $4,153   $5,198    -20%    $8,391   $9,722    -14%

    Germany            5,959    6,976    -15%    12,084   13,416    -10%
    Japan              3,856    3,529      9%     7,556    6,481     17%
    Korea              1,615      890     81%     2,601    1,640     59%
    Other              3,534    4,072    -13%     6,768    7,366     -8%
                       -----    -----             -----    -----
      Total
       International
       Sales          14,964   15,467     -3%    29,009   28,903      0%

                     -------  -------           -------  -------
        Total Sales  $19,117  $20,665     -7%   $37,400  $38,625     -3%
                     =======  =======           =======  =======


    Product Sales
        IOLs          $8,510   $8,787     -3%   $16,656  $16,735      0%
        ICLs          $5,652   $5,405      5%   $10,717   $9,684     11%
        Other         $4,955   $6,473    -23%   $10,027  $12,206    -18%
                      ------   ------           -------  -------
      Total          $19,117  $20,665     -7%   $37,400  $38,625     -3%
                     =======  =======           =======  =======



    STAAR Surgical Company
    Condensed Consolidated Balance Sheets
    (in 000's)
    Unaudited
                                                          July 3,   January 2,
                                                           2009        2009
                                                           ----        ----

    Cash and cash equivalents                              $5,754      $4,992
    Restricted cash                                         7,341         179
    Accounts receivable trade, net                          9,411       8,422
    Inventories                                            15,672      16,668
    Prepaids, deposits, and other current assets            1,876       2,009
                                                            -----       -----
       Total current assets                                40,054      32,270
                                                           ------      ------
    Property, plant, and equipment, net                     5,378       5,974
    Intangible assets, net                                  5,051       5,611
    Goodwill                                                7,711       7,538
    Other assets                                            1,132       1,189
                                                            -----       -----
       Total assets                                       $59,326     $52,582
                                                          =======     =======


    Accounts payable                                       $5,553      $6,626
    Line of credit                                          2,704       2,200
    Deferred income taxes - current                           282         282
    Obligations under capital leases - current              1,046         989
    Other current liabilities                              11,627      11,366
                                                           ------      ------
       Total current liabilities                           21,212      21,463
                                                           ------      ------
    Notes payable - long-term, net of discount              4,276       4,414
    Obligations under capital leases - long-term            1,182       1,335
    Deferred income taxes - long-term                         828         897
    Other long-term liabilities                             1,769       1,678
                                                            -----       -----
    Total liabilities                                      29,267      29,787

    Series A redeemable convertible preferred stock         6,776       6,768

    Common stock                                              347         295
    Additional paid-in capital                            148,992     138,811
    Accumulated other comprehensive income                  2,585       2,812
    Accumulated deficit                                  (128,641)   (125,891)
                                                         --------    --------
    Total stockholders' equity                             23,283      16,027
                                                           ------      ------
    Total liabilities, redeemable convertible preferred
     stock and stockholders' equity                       $59,326     $52,582
                                                          =======     =======



    STAAR Surgical Company
    Condensed Consolidated Statements of Cash Flows
    (in 000's)
    Unaudited
                                                       Six Months Ended
                                                       ----------------
                                                      July 3,    June 27,
                                                        2009        2008
                                                        ----        ----
    Cash flows from operating activities:
       Net loss                                      $(2,750)   $(11,485)
       Adjustments to reconcile net loss to
        net cash used in operating activities:
         Depreciation of property and equipment        1,156       1,340
         Amortization of intangibles                     390         418
         Amortization of discount                        152         118
         Fair value adjustment of warrant                  8           2
         Loss on disposal of property and equipment       29          84
         Stock-based compensation expense                902         825
         Loss on settlement of pre-existing
          distribution arrangement                         -       3,850
         Change in pension liability                     106          56
         Other                                           112        (130)
       Changes in working capital, net of business
        acquisition:
         Accounts receivable                          (1,173)     (2,716)
         Inventories                                     937       2,034
         Prepaids, deposits and other current assets     381        (487)
         Accounts payable                               (645)       (753)
         Other current liabilities                       233         714
                                                         ---         ---
            Net cash used in operating activities       (162)     (6,130)
                                                        ----      ------

    Cash flows from investing activities:
         Cash acquired in acquisition of Canon
          Staar, net of acquisition costs                  -       2,511
         Acquisition of property and equipment          (256)       (415)
         Proceeds from sale of property and equipment     81          89
         Proceeds from sale of short-term investments      -          79
         Restricted deposit with the Superior Court
          of Orange County                            (7,341)          -
         Net change in other assets                        5         (63)
                                                           -         ---
            Net cash provided by (used in)
             investing activities                     (7,511)      2,201
                                                      ------       -----

    Cash flows from financing activities:
         Borrowings under lines of credit                630       3,800
         Repayments of lines of credit                     -      (1,900)
         Repayment of capital lease lines of credit     (559)       (419)
         Net proceeds of public sale of equity
          securities                                   8,548           -
                                                       -----           -
            Net cash provided by financing
             activities                                8,619       1,481
                                                       -----       -----

    Effect of exchange rate changes on
     cash and cash equivalents                          (184)        404
                                                        ----         ---

    Decrease in cash and cash equivalents                762      (2,044)
    Cash and cash equivalents, at beginning
     of the period                                     4,992      10,895
                                                       -----      ------
    Cash and cash equivalents, at end of the period   $5,754      $8,851
                                                      ======      ======



    STAAR Surgical Company
    GAAP Reconciliation Tables
    (in 000's)
    Unaudited
                                Three Months Ended         Six Months Ended
                                ------------------         ----------------
                               July 3,     June 27,       July 3,     June 27,
                                2009         2008          2009         2008
                                ----         ----          ----         ----
             Adjusted EBITDA
    Net loss                   (1,088)     (2,545)       (2,750)     (11,485)
    Income taxes                  280         396           716          654
    Interest income                (5)        (63)           (8)         (91)
    Interest expense              399         222           632          423
    Depreciation                  581         538         1,156        1,340
    Amortization                  193         176           390          418
                                  ---         ---           ---          ---
    EBITDA                        360      (1,276)          136       (8,741)
                                  ---       ------          ---        ------
    Stock-based
     compensation                 294         388           902          825
    Cost of sales                   -           -             -        1,500
    Loss on settlement
     of pre-existing                -           -             -        3,850
     distribution
     arrangement                    -           -             -        -----
    Adjusted EBITDA               654        (888)        1,038       (2,566)
                                  ===        ====         =====       ======



                                 Three Months Ended 7/3/2009
                                 ---------------------------
     Sales in Constant Currency           Effect                 Three Months
                                   As      of                        Ended
                                Reported Currency  Ex-Currency     6/27/2008
                                -------- --------  -----------   ------------
    US                             4,153       -        4,153        5,198
    International                 14,964    (727)      15,691       15,467
                                  ----------------------------------------
    Total                         19,117    (727)      19,844       20,665
                                  ========================================

                                  Six Months Ended 7/3/2009
                                  -------------------------
     Sales in Constant Currency
                                          Effect                 Six Months
                                   As       of                       Ended
                                Reported Currency  Ex-Currency     6/27/2008
                                -------- --------  -----------   ------------
    US                             8,391       -       8,391         9,722
    International                 29,009  (1,325)     30,334        28,903
                                  ----------------------------------------
    Total                         37,400  (1,325)     38,725        38,625
                                  ========================================



                                           Q2 2009 vs. Q2 2008
                                           --------------------
     Sales in Constant Currency       As Reported         Ex-Currency
                                 --------------------------------------
                                 $Change   %Change     $Change  %Change
                                 --------------------------------------
    US                            (1,045)    -20%      (1,045)     -20%
    International                   (503)     -3%         224        1%
    Total                         (1,548)     -7%        (821)      -4%



     Sales in Constant Currency      As Reported          Ex-Currency
                                 --------------------------------------
                                 $Change   %Change     $Change  %Change
                                 --------------------------------------
    US                            (1,331)    -14%      (1,331)     -14%
    International                    106       0%       1,431        5%
    Total                         (1,225)     -3%         100        0%



                     Six Months       As Reported Six Months
     Statement of   % of  July 3, % of   June 27, Purchase  Ex Purchase  % of
      Operations    Sales  2009   Sales     2008  A/C Chgs  A/C Chgs    Sales
                    ---------------------------------------------------------
    Net sales       100%  $37,400  100%  $38,625      $-     $38,625     100%
    Cost of sales    44%   16,397   50%   19,336  (1,500)     17,836      46%
                           ------         ------   ------     ------
    Gross profit     56%   21,003   50%   19,289   1,500      20,789      54%
                           ------         ------   -----      ------
    Selling, general and
     administrative
     expenses:
       General
        and admini-
        strative     22%    8,137   21%    7,961       -       7,961      21%
       Marketing and
        selling      32%   11,811   37%   14,113       -      14,113      37%
       Research and
        development   8%    2,853   11%    4,075       -       4,075      11%
       Loss on
        settlement of
        pre-existing
        distribution
        arrangement             -   10%    3,850  (3,850)          -       0%
                              ---   --     -----   -----         ---
         Total selling,
          general and
          administrative
          expenses:  61%   22,801   78%   29,999  (3,850)     26,149      68%
                           ------   --    ------   -----      ------
    Operating loss   -5%   (1,798) -28%  (10,710)  5,350      (5,360)    -14%
                            -----   --    ------   -----       -----
    Other income
     (expense):                                                           0%
       Interest
        income        0%        8    0%       91       -          91       0%
       Interest
        expense      -2%     (632)  -1%     (423)      -        (423)     -1%
       Gain on foreign
        currency      1%      197    0%      144       -         144       0%
       Other income,
        net           1%      191    0%       67       -          67       0%
                                              --     ---          --
         Total other
          (expense)
          income,
          net        -1%     (236)   0%     (121)      -        (121)      0%
                              ---            ---     ---         ---
    Loss before
     provision for
     income taxes    -5%   (2,034) -28%  (10,831)  5,350      (5,481)    -14%
    Income tax
     provision        2%      716    2%      654       -         654       2%
                              ---            ---     ---         ---
    Net loss         -7%  $(2,750) -30% $(11,485) $5,350     $(6,135)    -16%
                            =====         ======   =====       =====
    Loss per share:
     basic and diluted     $(0.09)        $(0.39)  $0.18      $(0.21)
                             ====           ====    ====        ====
    Weighted average
     shares
     outstanding:
     basic
     and diluted           30,276         29,488  29,488      29,488
                           ======         ======  ======      ======


'/>"/>
SOURCE STAAR Surgical Company
Copyright©2009 PR Newswire.
All rights reserved


Related medicine news :

1. STAAR Surgical to Present at BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York
2. Review of STAARs Application for the Visian(R) Toric Implantable Collamer(R) Lens by FDA to Resume
3. Review of STAARs Application for the Visian(R) Toric Implantable Collamer(R) Lens by FDA to Resume
4. STAAR Surgical Announces Second Quarter 2009 Earnings Release Date And Conference Call
5. Richard A. Meier Appointed to STAAR Surgical Board of Directors
6. STAAR Surgical Completes Common Stock Offering
7. STAAR Surgical Receives Japanese Clearance for the KS-Ni Preloaded IOL Injector System
8. STAAR Surgical Announces First Quarter 2009 Earnings Release Date and Conference Call
9. STAAR Surgical Reports 14% Fourth Quarter Revenue Growth
10. STAAR Surgical Forms Team of Leading Ophthalmic Surgeons to Study the Use of Collamer(R) Material for Accommodating Intraocular Lenses
11. STAAR Surgical Reports 33% Third Quarter Revenue Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
(Date:6/24/2016)... ... 2016 , ... People across the U.S. are sharpening their pencils and honing ... contest in which patients and their families pay tribute to a genetic counselor by ... Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Venture Construction ... Classic Tournament held on June 20th at the Woodmont Country Club at 1201 ... Wings, an organization dedicated to helping service members that have been wounded in battle ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 If ... Leaders Scholarship is any indication, the future is in ... at www.diabetesscholars.org by the Diabetes Scholars Foundation ... the way of academic and community service excellence. ... since 2012, and continues to advocate for people with ...
Breaking Medicine Technology: